TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

被引：0
|
作者：
Chen, Qingxiao [1 ]
He, Jingsong [1 ]
Guo, Xing [1 ]
Chen, Jing [1 ]
Yang, Li [1 ]
Lin, Xuanru [1 ]
Li, Yi [1 ]
Zhang, Enfan [1 ]
Yang, Yang [1 ]
Wu, Wenjun [1 ]
He, Donghua [1 ]
Huang, He [1 ]
Liu, Shizhou [2 ]
Cai, Zhen [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Translat Med, Hangzhou 310003, Zhejiang, Peoples R China
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Loss of TET2 and TET3 in regulatory T cells unleashes effector function
    Xiaojing Yue
    Chan-Wang J. Lio
    Daniela Samaniego-Castruita
    Xiang Li
    Anjana Rao
    Nature Communications, 10
  • [42] Impact of Tet2 Deficiency, and of TET2 Mutations in Clonal Hematopoiesis, on Neutrophil/Granulocyte Immune Function
    Cook, Elina K.
    Luo, Michael
    Mewburn, Jeffrey
    Dunham-Snary, Kimberly J.
    Hindmarch, Charles
    Archer, Stephen L.
    Rauh, Michael J.
    BLOOD, 2021, 138
  • [43] The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia
    Zhao, Huihui
    Zhu Huayuan
    Yu, Zhu
    Li, Jianyong
    Qian, Sixuan
    BLOOD, 2017, 130
  • [44] The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia
    Zhao, Huihui
    Zhu, Huayuan
    Huang, Jiayu
    Zhu, Yu
    Hong, Ming
    Zhu, Han
    Zhang, Jingjing
    Li, Shan
    Yang, Lijia
    Lian, Yun
    Wang, Shuai
    Mao, Jianping
    Chen, Yaoyu
    Li, Jianyong
    Qian, Sixuan
    LEUKEMIA RESEARCH, 2018, 66 : 1 - 7
  • [45] In patients (pts) with acute myeloid leukemia (AML) a TET2 polymorphism is linked to TET2-mutation-associated clonal hematopoiesis (CH)
    Brauer, D.
    Grimm, J.
    Jentzsch, M.
    Bill, M.
    Goldmann, K.
    Schulz, J.
    Niederwieser, D.
    Platzbecker, U.
    Schwind, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 86 - 86
  • [46] Dysregulation of TET2 in hematologic malignancies
    Shigeru Chiba
    International Journal of Hematology, 2017, 105 : 17 - 22
  • [47] TET2, an “ambiguous” player in inflammation
    Ana María Espinosa-Oliva
    Miguel Angel Burguillos
    NeuralRegenerationResearch, 2020, 15 (08) : 1481 - 1482
  • [48] The Potential Equivalents of TET2 Mutations
    Pasca, Sergiu
    Jurj, Ancuta
    Zdrenghea, Mihnea
    Tomuleasa, Ciprian
    CANCERS, 2021, 13 (07)
  • [49] TET2 mutations in childhood leukemia
    Langemeijer, S. M. C.
    Jansen, J. H.
    Hooijer, J.
    van Hoogen, P.
    Stevens-Linders, E.
    Massop, M.
    Waanders, E.
    van Reijmersdal, S. V.
    Stevens-Kroef, M. J. P. L.
    Zwaan, C. M.
    van den Heuvel-Eibrink, M. M.
    Sonneveld, E.
    Hoogerbrugge, P. M.
    van Kessel, A. Geurts
    Kuiper, R. P.
    LEUKEMIA, 2011, 25 (01) : 189 - 192
  • [50] Mutation in TET2 in Myeloid Cancers
    Delhommeau, Francois
    Dupont, Sabrina
    Della Valle, Veronique
    James, Chloe
    Trannoy, Severine
    Masse, Aline
    Kosmider, Olivier
    Le Couedic, Jean-Pierre
    Robert, Fabienne
    Alberdi, Antonio
    Lecluse, Yann
    Plo, Isabelle
    Dreyfus, Francois J.
    Marzac, Christophe
    Casadevall, Nicole
    Lacombe, Catherine
    Romana, Serge P.
    Dessen, Philippe
    Soulier, Jean
    Viguie, Franck
    Fontenay, Michaela
    Vainchenker, William
    Bernard, Olivier A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22): : 2289 - 2301
12345